La Jolla Pharmaceutical price target raised to $32 from $27 at Wedbush Wedbush increased its price target on La Jolla after the company's GCS-100 drug facilitated statistically significant improvement in kidney function in CKD patients in a Phase 2a trial. The firm thinks the company will respond by taking the drug forward in CKD, and by activating clinical trials in multiple pipeline candidates. Wedbush keeps an Outperform rating on the stock.
News For LJPC From The Last 14 Days
Check below for free stories on LJPC the last two weeks.